2026-04-29T12:23:02Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/253722025-12-18T13:00:52Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19608

00925njm 22002777a 4500 dc Colombe, Soledad author Funke, Silvia author Koch, Anders author Haverkate, Manon author Monge Corella, Susana author Barret, Anne-Sophie author Vaughan, Aisling author Hahné, Susan author van Ewijk, Catharina author Emborg, Hanne-Dorthe author von Schreeb, Sebastian author Díaz, Asunción author Olmedo, Carmen author Zanetti, Laura author Levy-Bruhl, Daniel author de Sousa, Luis Alves author Hagan, José author Nicolay, Nathalie author Pebody, Richard author 2024-08 Background: In 2022, a global monkeypox virus (MPXV) clade II epidemic occurred mainly among men who have sex with men. Until early 1980s, European smallpox vaccination programmes were part of worldwide smallpox eradication efforts. Having received smallpox vaccine > 20 years ago may provide some cross-protection against MPXV. Aim: To assess the effectiveness of historical smallpox vaccination against laboratory-confirmed mpox in 2022 in Europe.MethodsEuropean countries with sufficient data on case vaccination status and historical smallpox vaccination coverage were included. We selected mpox cases born in these countries during the height of the national smallpox vaccination campaigns (latest 1971), male, with date of onset before 1 August 2022. We estimated vaccine effectiveness (VE) and corresponding 95% CI for each country using logistic regression as per the Farrington screening method. We calculated a pooled estimate using a random effects model. Results: In Denmark, France, the Netherlands and Spain, historical smallpox vaccination coverage was high (80-90%) until the end of the 1960s. VE estimates varied widely (40-80%, I2 = 82%), possibly reflecting different booster strategies. The pooled VE estimate was 70% (95% CI: 23-89%). Conclusion: Our findings suggest residual cross-protection by historical smallpox vaccination against mpox caused by MPXV clade II in men with high uncertainty and heterogeneity. Individuals at high-risk of exposure should be offered mpox vaccination, following national recommendations, regardless of prior smallpox vaccine history, until further evidence becomes available. There is an urgent need to conduct similar studies in sub-Saharan countries currently affected by the MPXV clade I outbreak. the excitatory neurons cluster (Done from ReviGO). Euro Surveill. 2024 Aug;29(34):2400139 10.2807/1560-7917.ES.2024.29.34.2400139 1560-7917 1025-496X Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin 39176988 https://hdl.handle.net/20.500.12105/25372 Europe Childhood smallpox vaccination Monkeypox mpox Screening method Vaccine effectiveness Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022